Behavioral Considerations Abound In FDA Review Of Truvada For PrEP
Executive Summary
The potential dangers associated with medication non-adherence, failure to obtain regular HIV testing and “risk compensation” were cited by critics as reasons not to approve Truvada for pre-exposure prophylaxis. Although Gilead’s proposed REMS targets these behaviors, it remains to be seen whether such risk management efforts will have an impact.